Publications by authors named "J L Freddo"
Purpose: New antiviral agents with activity against hepatitis C virus (HCV) are needed to optimize treatment for chronic hepatitis C (CHC). We evaluated the pharmacokinetics of setrobuvir (a non-nucleoside HCV polymerase inhibitor) in healthy volunteers (study 1 & 2) and its antiviral efficacy in patients with genotype 1, noncirrhotic treatment-naive CHC (study 3).
Methods: Three studies investigated the pharmacokinetics and pharmacodynamics of setrobuvir.
Background: ANA773, an oral prodrug of a small-molecule Toll-like receptor (TLR)7 agonist, induces a dose-related decrease in serum HCV RNA levels in chronic hepatitis C patients.
Methods: The prodrug ANA773 was administered to healthy individuals and chronic hepatitis C patients. At different time points during the course of treatment, modulation of the phenotype and function of peripheral leukocytes were evaluated to determine the role of distinct immune cells on the clinical outcome of therapy.
Background: The ANA773 is an oral prodrug of a small-molecule toll-like receptor (TLR)7 agonist. Preclinical and healthy volunteer clinical studies with ANA773 have demonstrated induction of endogenous interferon-α (IFN-α) of multiple subtypes, which supports the potential utility in the treatment of chronic hepatitis C virus (HCV) infection.
Aim: To examine safety, tolerability, pharmacodynamics, pharmacokinetics and anti-viral activity of ANA773.
Article Synopsis
- Axitinib is a targeted oral medication shown to be effective in treating metastatic renal-cell cancer in patients previously treated with cytokines, with a 44.2% objective response rate.
- The study involved 52 patients, tracking primary outcomes like response rate and secondary outcomes such as duration of response and overall survival, revealing a median response duration of 23 months.
- While there were significant benefits, adverse side effects, particularly treatment-related hypertension, were common but manageable with medication.
Purpose: We studied the safety, clinical activity, and pharmacokinetics (PK) of AG-013736, an oral receptor tyrosine kinase inhibitor of vascular endothelial cell growth factor, platelet-derived growth factor, and c-Kit, in patients with advanced cancer.
Patients And Methods: Patients received fixed doses of AG-013736 orally in 28-day cycles. In the first cohort, patients initially received two single test doses of AG-013736 (10 and 30 mg); subsequent dosing was determined by individual PK parameters.